KIDNEY curative treatment – II : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for sure and cure treatment on KIDNEY problems. Dr. Jyotsna Lad (CMO, Modern Homeopathy) for awareness and guidance on KIDNEY diseases. It is curative line of treatment for Cancer, Liver Cirrhosis, Heart, Asthma, Arthritis, Brain & Blood disorders and all incurable diseases.

Modern Homeopathy for KIDNEY treatment – 3A : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 3B : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 4A : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 4B : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

LIVER diseases curative treatment by Modern Homeopathy : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

Modern Homeopathy helps you for awareness, Guidance and curative treatment on LIVER CIRRHOSIS with Dr. Vijaykumar Mane (CEO, Modern Homeopathy) . Now you can enjoy healthy and happy life with Modern Homeopathy. It is curative line treatment for Cancer, Kidney, Cirrhosis, Heart, Brain disorders, Gastro-Intestinal problems, Chronic failure, Nephritic Syndrome and other incurable diseases.

LIVER diseases treatment : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

HEART disease curative treatment by Modern Homeopathy – I : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

Modern Homeopathy helps you for Awareness, Guidance and Curative treatment on HEART disease with Dr. Vijaykumar Mane (CEO, Modern Homeopathy). Now you can enjoy Healthy and Happy life with Modern Homeopathy…..it is curative line of treatment for Cancer, Kidney, Liver Cirrhosis, Heart, Diabetes, Nephritic Syndrome, Allergy, Rheumatic Diseases, Arthritis, Asthma, Blood and Brain disorders, Gastro-Intestinal Problems, Chronic failure and other incurable diseases.

HEART disease curative treatment by Modern Homeopathy – 1A : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

HEART disease curative treatment by Modern Homeopathy – 1B : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

KIDNEY curative treatment : Dr. Nayana Bhosale (MO, Modern Homeopathy)

Modern Homeopathy for your KIDNEY disease Awareness, Guidance and curative treatment

Modern Homeopathy for curative treatment on KIDNEY- I : Dr. Nayana Bhosale (MO, Modern Homeopathy)

Modern Homeopathy for curative treatment onKIDNEY- II : Dr. Nayana Bhosale (MO, Modern Homeopathy)

KIDNEY curative treatment – I : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for sure and cure treatment on KIDNEY problems. Dr. Jyotsna Lad (CMO, Modern Homeopathy) for awareness and guidance on KIDNEY diseases. It is curative line of treatment for Cancer, Liver Cirrhosis, Heart, Asthma, Arthritis, Brain & Blood disorders and all incurable diseases.

Modern Homeopathy for KIDNEY treatment – 1A : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 1B : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 2A : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

Modern Homeopathy for KIDNEY treatment – 2B : Dr. Jyotsna Lad (CMO, Modern Homeopathy)

CANCER curative treatment by Modern Homeopathy : Dr. Vijaykumar Mane (CEO, Modern Homeopathy)

Modern Homeopathy for CANCER awareness and curative treatment by Dr. Vijaykumar Mane (CEO, Modern Homeopathy) . Now you can enjoy healthy and happy life with Modern Homeopathy. It is curative line of treatment for Liver Cirrhosis, Kidney, Heart, Brain disorders, Gastro-Intestinal problems, Chronic failure, Nephritic Syndrome and other incurable diseases.

Treatments for IPF (Idiopathic Pulmonary Fibrosis) – 4

Idiopathic Pulmonary Fibrosis

Acute Exacerbation (AE):

– It is an unexplained worsening or development of dyspnoea within 30 days with new radiological infiltrates at HRCT abnormality often super imposed on background consistent with UIP pattern.

– The yearly incident of AE-IPF is poor, with mortality ranging from 78% to 96%.
Other causes of AEIPF such as pulmonary embolism, congestive heart failure, pneumothorax or infectin need to be excluded.

– Pulmonary infection has to be ruled out by endotracheal aspirate or BAL.

– Many patients experiencing acute deterioration require intensive care treatment, particularly when respiratory failure is associated with hemodynamic instability significant co-morbidity or severe hypoxemia.

– Mortality during hospitalization is high.

– Mechanical ventilation should be introduced only after carefully weighing the patients long-term prognosis and whenever possible, the patient’s wishes.

Prognosis:

Clinical causes of IPF are unpredictable.
– Prognosis of IPF is associated with estimated median survival time 2-5 years after diagnosis.
5 years survival for IPF ranges between 20-40 %.

– Mortality rate higher than that of a number of malignancies including colon cancer, multiple myeloma and bladder cancer.

– Recently a multidimensional index and staging system has been proposed to predict mortality in IPF.

– The name of the index is GAP and is based on gender (G) age (A), and two lung physiology variable (P) that are commonly measured in clinical practice to predict mortality in IPF.

– The highest stage of GAP (Stage III) has been found to be associated with a 39% risk of mortality at 1 year.
This model has been evaluated in IPF and other ILDs and shown good performance in predicting mortality in all main ILD subtypes.

– In addition to clinical and physiological parameters to predict how rapidly patients with IPF might progress genetic and molecular features are also associated with IPF mortality.

– It has been shown that IPF patients who have a specific genotype in the mucin MUC 58 gene polymorphism experience slower decline in FVC and significantly improved survival.

– Even if such data are interesting from a scientific point of view, the application in the clinical routine of a prognostic model based on the specific genotypes is still impossible.

Epidemiology:

– IPF is the most common form of IIP.

– The prevalence of IPF has been estimated between 14 and 42.7 per 100,000 persons based on a USA analysis of health care claims date with a variation depending on the case definitions used in this analysis.

– IPF is more common in men than in women and is usually diagnosed in people over 50 years of age.
The incidence of IPF is 6.8-16.3 per 100,000 persons.

– Approximately 30,000-35,000 new patients will be diagnosed with IPH each year.

– IPF was the most common diagnosis (28%) followed by connective tissue disease – related ILD (14%), hypersensitivity pneumonitis (7%) and non-specific interstitial pneumonia (NSIP) (7%).

for more details visit MODERN HOMEOPATHY…..the curative line of treatment

Treatments for IPF (Idiopathic Pulmonary Fibrosis) – 3

Long Term Oxygen Therapy (LTOT):
In 20%, IPF guidelines ‘Oxygen Therapy’, or supplementary oxygen for home use, became a strong recommendation for use in those patients with clinically significant resting hypoxemia.

Although oxygen therapy has not been shown to improve survival in IPF some data indicate an improvement in exercise capacity.

Pulmonary Rehabilitation:
Fatigue and loss of muscular mass are common and disabling problems for patients with IPF.

Pulmonary rehabilitation may alleviate the over symptoms of IPF ad improve functional status by stabilizing and reversing the extra-pulmonary features of the disease.

Palliative Care:
It focuses on reducing symptoms and improving the comfort of patients rather than treating the disease.

This may include treatment of worsening symptoms with the use of chronic Opioids for severe dyspnea and cough.
Further oxygen therapy may be useful for palliation of dyspnea in hypoxemia patients.

Palliative care also includes relief of physical and emotional suffering and psychosocial support for patients and care givers.

With disease progression patients may experience fear, anxiety and depression.
Psychological counseling should be considered.

In selected cases of particularly severe dyspnea morphine could be considered. It reduces dyspnea, anxiety and cough.

Management and follow up:
IPF is often misdiagnosed when physiological or imagine data suggest the presence of ILD leading to delay in accessing appropriate care.

After diagnosis of IPF, and appropriate treatment choice according to symptoms and stage of diseases, a close follow-up should be applied.

Due to the high variable course of disease, the higher incidence of complications like lung cancer, a routine evaluation every 3 to 6 months, including spirometry (body plethysmography) diffusion capacity testing, chest x-ray, 6MWT, assessment of dyspnea, quality of life, oxygen requirement is mandatory.

For more visit www.modernhomeopathy.co.in
MODERN HOMEOPATHY……….for the curative line of treatment

Treatments for IPF (Idiopathic Pulmonary Fibrosis) – 2

Pulmonary Fibrosis

Pulmonary Fibrosis

Nintedanib:
Nintedanibis an investigational orally-administered triple angiokinase inhibitor that targets receptor tyrosine.
Kinases involved in the regulations of angiogenesis -fibroblasts growth factor receptor (FGFR), platelet derived growth factor receptor (PDGFR) which have also been implicates.
Nintendanib, like Pirfenidone was approved for the treatment of IPF by the U.S. FDA in October 2014.

Future Therapeutic Options:
Many agents are investigated I Phase II clinical trials for IPF, including the ‘monoclonal antibodies’ simtuzumab tralokimob, lebrikizumab and FG-2019, a lysophoshpatidic acid receptor antagonist (BMS=986020).

A phase II study of STX-100 is also ongoing.

These molecules are directed against several growth factors and cytokines that are known to play a role in the proliferation, activation, differentiation or inappropriate survival of fibroblasts.

Non Pharmacological Interventions:

Lung Transplantation:
Lung Transplantation may be suitable for those patients, physically eligible to undergo a major transplant operation.

In IPF patients, lung transplantation reduces the risk of death by 75% as compared with patients who remain on the waiting list.

Since the introduction of the lung allocation score (LAS), which prioritizes transplant candidates based on survival for lung transplantation in the USA.

Symptomatic patients with IPF younger than 65 years of age and with a body mass index (BMI) ≤ 26kg/m² should be referred for lung transplantation, but there are no clear data to guide the precise timing for LT.

Bilateral lung transplantation is superior to single lung transplantation in patients with IPF.
Five-year survival rates after lung transplantation IPF are estimated at between 50-56%.

for more details visit “MODERN HOMEOPATHY………the curative line of treatment”.
our website www.modernhomeopathy.co.in